Abstract： Objective To observe the influence of trimetazidine therapy on N-terminal pro-brain natriuretic peptide (NT-proBNP) and exercise tolerance in patients with congestive myocardial failure caused by coronary heart disease. Methods A total of 8 patients with congestive myocardial failure caused by coronary heart disease were randomized into trimetazidine group and routine therapy group, The levels of NT-proBNP, 2-dimensional echocardiography (DE) were detected and 6-mintute walk test was done for all patients at the baseline and 6 months after the therapy. Results The levels of NT-proBNP and LVEDV were significantly lower(P<0.05), but LVEF became higher (P<0.05), and the mean distance of 6-mintute walk test significantly increased (P<0.05) in trimetazidine group than those in routine therapy group and the baseline. Conclusion With trimetazidine therapy,the level of NT-proBNP decreases in patients with coronary heart disease complicated with congestive myocardial failure, meanwhile paitent's exercise tolerance is significantly improved.